Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy

Graves Orbitopathy Clinical Trial

Official title: Single-centre, Safety and Efficacy, Open-label Study Evaluating Antithymocyte Globulin Treatment in Subjects With Graves Orbitopathy

Status Recruiting

Clinical Trial Summary

The overall objective of the study is to evaluate the safety and efficacy of rabbit antithymocyte globulin in the treatment of Graves orbitopathy (GO) after ineffective treatment with moderate-to-high doses of glucocorticoids.

Clinical Trial Description

This is a prospective interventional, single-center study examining the safety and efficacy of rabbit antithymocyte globulin (rATG) in adult patients with active moderate-to-severe GO after ineffective treatment with moderate-to-high doses of glucocorticoids. All enrolled participants will receive 0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.

In order to assess efficacy and safety of the treatment, patients will be evaluated at baseline and at 6, 12, 24 and 48 weeks. Baseline and subsequent evaluation will involve medical history, physical examination, including detailed eye examination, laboratory assessment (thyroid-stimulating hormone [TSH], flow cytometry, TSH-receptor antibodies, CBC) and orbital magnetic resonance imaging (MRI). ;

Related Conditions & MeSH terms

• Graves Ophthalmopathy
• Graves Orbitopathy

• NCT number: NCT05199103
• Study type: Interventional
• Source: Medical University of Silesia
• Contact: Gabriela Handzlik, Ph.D.
• Phone: 322591202
• Email: ghandzlik@sum.edu.pl
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2020
• Completion date: December 31, 2023